JPMorgan Chase & Co. lifted its holdings in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP – Free Report) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,301 shares of the company’s stock after buying an additional 255 shares during the period. JPMorgan Chase & Co. owned approximately 0.13% of Invesco Pharmaceuticals ETF worth $355,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in shares of Invesco Pharmaceuticals ETF during the 4th quarter valued at $943,000. Jones Financial Companies Lllp raised its position in shares of Invesco Pharmaceuticals ETF by 195.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,176 shares of the company’s stock worth $180,000 after purchasing an additional 1,440 shares during the period. Commonwealth Retirement Investments LLC purchased a new stake in shares of Invesco Pharmaceuticals ETF during the fourth quarter valued at $401,000. MGB Wealth Management LLC boosted its position in shares of Invesco Pharmaceuticals ETF by 11.9% in the 4th quarter. MGB Wealth Management LLC now owns 21,976 shares of the company’s stock valued at $1,815,000 after purchasing an additional 2,345 shares during the period. Finally, Grimes & Company Inc. acquired a new position in shares of Invesco Pharmaceuticals ETF in the 4th quarter valued at $354,000.
Invesco Pharmaceuticals ETF Stock Performance
Shares of PJP opened at $80.86 on Friday. The company has a market capitalization of $243.39 million, a PE ratio of 19.60 and a beta of 0.56. The company’s 50 day moving average price is $82.07 and its 200 day moving average price is $84.32. Invesco Pharmaceuticals ETF has a 52 week low of $72.25 and a 52 week high of $89.87.
About Invesco Pharmaceuticals ETF
PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Read More
- Five stocks we like better than Invesco Pharmaceuticals ETF
- What Are Some of the Best Large-Cap Stocks to Buy?
- The Most Inspiring Small Businesses of 2025 [Survey]
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Microsoft Crushes Earnings, What’s Next for MSFT Stock?
- What is the Australian Securities Exchange (ASX)
- McDonald’s Insiders Sell Shares! Investors Should Do the Opposite
Receive News & Ratings for Invesco Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
